Podcast Episodes
Back to Search407: The mysterious case of Eli Lilly's obesity drug
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair…
3 months, 3 weeks ago
406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America.
The Food and Dru…
3 months, 4 weeks ago
405: An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and D…
4 months ago
404: What RevMed's pancreatic cancer drug meant for one patient
Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech sto…
4 months, 1 week ago
403: Biotech exec Jeremy Levin on the industry's strategic turning point
On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Savin…
4 months, 2 weeks ago
402: Guarding biotech from China and big bets in longevity
On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science …
4 months, 3 weeks ago
401: Makary’s departure and Cassidy’s tenuous Senate seat
This week’s episode of “The Readout LOUD” is all about health politics.
We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why h…
5 months ago
400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles
On this week’s episode of "The Readout LOUD," we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO.
Plus, Elai…
5 months, 1 week ago
399: Hair-raising trial results, and Servier’s M&A wishlist
Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma…
5 months, 2 weeks ago
398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts
How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugma…
5 months, 3 weeks ago